Completing the RWHAP Part A Program Terms Report (PTR)
Resource updated 06/27/2024
Resource updated 06/27/2024
Resource updated 10/24/2023
Resource updated 05/11/2023
Resource updated 12/19/2023
Resource updated 10/18/2023
Resource updated 05/10/2023
Resource updated 09/18/2023
Resource from the RWHAP Best Practices Compilation updated on 11/13/2023
RWHAP Technical Assistance Provider updated on 06/11/2024
Blog updated 03/28/2024
Resource from the RWHAP Best Practices Compilation updated on 11/01/2023
Resource updated 01/05/2024
From the HRSA HIV/AIDS Bureau Listserv, 12/16/22
In a single-center restrospective cohort study, patients with extensive treatment experience and history of virologic failure and multi-drug resistance underwent simplification of ARV salvage regimens with a median pill burden reduction of six pills per day. This strategy led to high rates of virologic suppression.
Resource (Conference Presentation) updated 09/14/2023
The first long-acting injectable antiretroviral therapy (LAI ART) formulation was FDA-approved January 2021. Drawing on the Consolidated Framework on Implementation Research, this mixed methods study assessed knowledge, attitudes, practices, and perceived barriers and facilitators related to implementation of LAI ART in NYC among HIV clinic staff and people with HIV.
Resource (Conference Presentation) updated 09/14/2023
We conducted semi-structured interviews with service providers to investigate current barriers, potential opportunities, estimated costs, and anticipated outcomes of program expansion for food, financial, transportation, and housing support services for RWHAP clients.
Resource (Conference Presentation) updated 09/14/2023
We used a data-driven, mixed method approach to develop a community planning and budget tool to inform resource allocation decision-making to achieve health equity in HIV outcomes among RWHAP clients in the Minneapolis-St. Paul Transitional Grant Area.
Resource (Conference Presentation) updated 09/14/2023